BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

830 related articles for article (PubMed ID: 14559801)

  • 1. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.
    Yan PS; Shi H; Rahmatpanah F; Hsiau TH; Hsiau AH; Leu YW; Liu JC; Huang TH
    Cancer Res; 2003 Oct; 63(19):6178-86. PubMed ID: 14559801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
    Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
    Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
    Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
    Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
    Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
    Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
    Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
    Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers.
    Dammann R; Yang G; Pfeifer GP
    Cancer Res; 2001 Apr; 61(7):3105-9. PubMed ID: 11306494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
    Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
    Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
    Stirzaker C; Song JZ; Davidson B; Clark SJ
    Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
    Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
    Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
    Soejima H; Nakagawachi T; Zhao W; Higashimoto K; Urano T; Matsukura S; Kitajima Y; Takeuchi M; Nakayama M; Oshimura M; Miyazaki K; Joh K; Mukai T
    Oncogene; 2004 May; 23(25):4380-8. PubMed ID: 15007390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
    Liu L; Yoon JH; Dammann R; Pfeifer GP
    Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site.
    Zinn RL; Pruitt K; Eguchi S; Baylin SB; Herman JG
    Cancer Res; 2007 Jan; 67(1):194-201. PubMed ID: 17210699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
    Ueki T; Walter KM; Skinner H; Jaffee E; Hruban RH; Goggins M
    Oncogene; 2002 Mar; 21(13):2114-7. PubMed ID: 11960385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.